Replies to post #87008 on NanoViricides Inc. (NNVC)

[noretreat]

Yep. Of course, your source is in business to perform the studies....

The point is that the "promise" made last year for tox by "June 30 +/- 3 months" was NOT for non-GLP tox.

And the question about what the next round of delays will be should be part of an stockholder "office pool", so at least someone will come out a winner.

[changes_iv]

Use of antiretrovirals for treatment and prevention of HIV infection

Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering when use is made of a potent ARV regimen, particularly in early stages of the disease.

Since 2013, WHO also recommends the ARV use for the prevention of HIV infection, particularly for pregnant women, young children, and key populations exposed to HIV risk. Countries are now following to adapt and implement these recommendations within own epidemiological settings.

WHO is also working to improve scaling up of ARV use in developing countries by optimizing drugs and diagnostics and enhancing community engagement.

source: http://www.who.int/hiv/topics/treatment/en/

related: A new era of antiretroviral drug toxicity -
http://www.ncbi.nlm.nih.gov/pubmed/19430091

NanoViricides Reports It Has Successfully Improved HIVCide Drug Candidate in Cell Culture Studies September 16, 2013 07:00 AM Eastern Daylight Time

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB:NNVCD) (the "Company") reports that it has successfully improved upon its previous lead anti-HIV drug candidate, based on cell culture studies. An improved broad-spectrum anti-HIV nanoviricide that inhibited two distinctly different types of HIV-1 viruses equally well has been identified. This drug candidate also exhibited a very large therapeutic index. The Company has previously reported that it is optimizing the anti-HIV drug candidate. These cell culture studies were conducted by Southern Research Institute, Frederick, MD.

The Company has previously reported unprecedented anti-HIV efficacy from our previous anti-HIV drug candidate, matching or exceeding the effectiveness level of a three drug HAART cocktail in the standard humanized mouse model studies.

With further optimization, the Company believes that it has now achieved extremely high efficacy levels for its lead and backup HIVCide candidates. Further optimization of the nanomicelle portion of the anti-HIV drug candidates is now in progress.

source: http://www.businesswire.com/news/home/20130916005563/en/NanoViricides-Reports-Successfully-Improved-HIVCide-Drug-Candidate